Insider Transaction Report for Contineum Therapeutics, Inc.

Carmine N. Stengone, CEO and President of Contineum Therapeutics, Inc., reported a series of transactions on July 8, 2026. Stengone acquired 2,500 shares of Class A Common Stock at $1.01 per share and disposed of 2,500 shares at $16.00 per share. Concurrently, Stengone exercised a stock option to buy 2,500 shares of Class A Common Stock at an exercise price of $1.01 per share, with the option itself being a right to buy. These transactions were executed under a 10b5-1 trading plan. Following these transactions, Stengone directly owns 17,217 shares of Class A Common Stock and has a total of 279,430 shares underlying vested stock options. The report is Form 4.